1
|
Thygesen K, Alpert JS, Jaffe AS, Simoons
ML, Chaitman BR and White HD: Third universal definition of
myocardial infarction. J Am Coll Cardiol. 60:1581–1598. 2012.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Swynghedauw B: Molecular mechanisms of
myocardial remodeling. Physiol Rev. 79:215–262. 1999. View Article : Google Scholar : PubMed/NCBI
|
3
|
Nian M, Lee P, Khaper N and Liu P:
Inflammatory cytokines and postmyocardial infarction remodeling.
Circ Res. 94:1543–1553. 2004. View Article : Google Scholar : PubMed/NCBI
|
4
|
Sun M, Dawood F, Wen WH, Chen M, Dixon I,
Kirshenbaum LA and Liu PP: Excessive tumor necrosis factor
activation after infarction contributes to susceptibility of
myocardial rupture and left ventricular dysfunction. Circulation.
110:3221–3228. 2004. View Article : Google Scholar : PubMed/NCBI
|
5
|
Regula KM and Kirshenbaum LA: Apoptosis of
ventricular myocytes: A means to an end. J Mol Cell Cardiol.
38:3–13. 2005. View Article : Google Scholar
|
6
|
van den Borne SW, Diez J, Blankesteijn WM,
Verjans J, Hofstra L and Narula J: Myocardial remodeling after
infarction: The role of myofibroblasts. Nat Rev Cardiol. 7:30–37.
2010. View Article : Google Scholar
|
7
|
Zamilpa R and Lindsey ML: Extracellular
matrix turnover and signaling during cardiac remodeling following
MI: Causes and consequences. J Mol Cell Cardiol. 48:558–563. 2010.
View Article : Google Scholar :
|
8
|
Fan Z and Guan J: Antifibrotic therapies
to control cardiac fibrosis. Biomater Res. 20:132016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Urbanelli L, Magini A, Buratta S, Brozzi
A, Sagini K, Polchi A, Tancini B and Emiliani C: Signaling pathways
in exosomes biogenesis, secretion and fate. Genes (Basel).
4:152–170. 2013. View Article : Google Scholar
|
10
|
Lin J, Li J, Huang B, Liu J, Chen X, Chen
XM, Xu YM, Huang LF and Wang XZ: Exosomes: Novel biomarkers for
clinical diagnosis. Scientific World Journal. 2015:6570862015.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Ha D, Yang N and Nadithe V: Exosomes as
therapeutic drug carriers and delivery vehicles across biological
membranes: Current perspectives and future challenges. Acta Pharm
Sin B. 6:287–296. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Théry C, Zitvogel L and Amigorena S:
Exosomes: Composition, biogenesis and function. Nat Rev Immunol.
2:569–579. 2002. View
Article : Google Scholar : PubMed/NCBI
|
13
|
Batrakova EV and Kim MS: Development and
regulation of exosome-based therapy products. Wiley Interdiscip Rev
Nanomed Nanobiotechnol. 8:744–757. 2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Batrakova EV and Kim MS: Using exosomes,
naturally-equipped nanocarriers, for drug delivery. J Control
Release. 219:396–405. 2015. View Article : Google Scholar : PubMed/NCBI
|
15
|
Boon RA and Dimmeler S: MicroRNAs in
myocardial infarction. Nat Rev Cardiol. 12:135–142. 2015.
View Article : Google Scholar
|
16
|
Sun T, Dong YH, Du W, Shi CY, Wang K,
Tariq MA, Wang JX and Li PF: The role of microRNAs in myocardial
infarction: From molecular mechanism to clinical application. Int J
Mol Sci. 18:2017. View Article : Google Scholar
|
17
|
Wang J, Huang W, Xu R, Nie Y, Cao X, Meng
J, Xu X, Hu S and Zheng Z: MicroRNA-24 regulates cardiac fibrosis
after myocardial infarction. J Cell Mol Med. 16:2150–2160. 2012.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Roy S, Khanna S, Hussain SR, Biswas S,
Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ and Sen CK: MicroRNA
expression in response to murine myocardial infarction: miR-21
regulates fibroblast metalloprotease-2 via phosphatase and tensin
homologue. Cardiovasc Res. 82:21–29. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Yuan J, Chen H, Ge D, Xu Y, Xu H, Yang Y,
Gu M, Zhou Y, Zhu J, Ge T, et al: Mir-21 promotes cardiac fibrosis
after myocardial infarction via targeting Smad7. Cell Physiol
Biochem. 42:2207–2219. 2017. View Article : Google Scholar : PubMed/NCBI
|
20
|
Thum T, Gross C, Fiedler J, Fischer T,
Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et
al: MicroRNA-21 contributes to myocardial disease by stimulating
MAP kinase signalling in fibroblasts. Nature. 456:980–984. 2008.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
22
|
Park H, Ku SH, Park H, Hong J, Kim D, Choi
BR, Pak HN, Lee MH, Mok H, Jeong JH, et al: RAGE siRNA-mediated
gene silencing provides cardioprotection against ventricular
arrhythmias in acute ischemia and reperfusion. J Control Release.
217:315–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Bala S, Csak T, Momen-Heravi F, Lippai D,
Kodys K, Catalano D, Satishchandran A, Ambros V and Szabo G:
Biodistribution and function of extracellular miRNA-155 in mice.
Sci Rep. 5:107212015. View Article : Google Scholar : PubMed/NCBI
|
24
|
National Research Council (US) Institute
for Laboratory Animal Research: Guide for the Care and Use of
Laboratory Animals. National Academies Press; Washington, DC:
1996
|
25
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Wang B, Hao J, Jones SC, Yee MS, Roth JC
and Dixon IM: Decreased Smad 7 expression contributes to cardiac
fibrosis in the infarcted rat heart. Am J Physiol Heart Circ
Physiol. 282:H1685–H1696. 2002. View Article : Google Scholar : PubMed/NCBI
|
28
|
Cheng Y and Zhang C: MicroRNA-21 in
cardiovascular disease. J Cardiovasc Transl Res. 3:251–255. 2010.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Oudit GY and Penninger JM: Cardiac
regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res.
82:250–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
30
|
Oudit GY, Sun H, Kerfant BG, Crackower MA,
Penninger JM and Backx PH: The role of phosphoinositide-3 kinase
and PTEN in cardiovascular physiology and disease. J Mol Cell
Cardiol. 37:449–471. 2004. View Article : Google Scholar : PubMed/NCBI
|
31
|
Tao H, Zhang JG, Qin RH, Dai C, Shi P,
Yang JJ, Deng ZY and Shi KH: LncRNA GAS5 controls cardiac
fibroblast activation and fibrosis by targeting miR-21 via
PTEN/MMP-2 signaling pathway. Toxicology. 386:11–18. 2017.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Chi JS and Kloner RA: Stress and
myocardial infarction. Heart. 89:475–476. 2003. View Article : Google Scholar : PubMed/NCBI
|
33
|
Travers JG, Kamal FA, Robbins J, Yutzey KE
and Blaxall BC: Cardiac fibrosis: The fibroblast awakens. Circ Res.
118:1021–1040. 2016. View Article : Google Scholar : PubMed/NCBI
|
34
|
Liu Gu H, Li Z, Xie Y, Yao Y, Zhu J, Xu Y,
Dai J, Zhong Q, Zhu CH, et al: Serum-derived extracellular vesicles
protect against acute myocardial infarction by regulating
miR-21/PDCD4 signaling pathway. Front Physiol. 9:3482018.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Khan M, Nickoloff E, Abramova T, Johnson
J, Verma SK, Krishnamurthy P, Mackie AR, Vaughan E, Garikipati VN,
Benedict C, et al: Embryonic stem cell-derived exosomes promote
endogenous repair mechanisms and enhance cardiac function following
myocardial infarction. Circ Res. 117:52–64. 2015. View Article : Google Scholar : PubMed/NCBI
|
36
|
Catalanotto C, Cogoni C and Zardo G:
MicroRNA in control of gene expression: An overview of nuclear
functions. Int J Mol Sci. 17:2016. View Article : Google Scholar : PubMed/NCBI
|
37
|
He He L, Lim X, de Stanchina LP, Xuan E,
Liang Z, Xue Y, Zender W, Magnus L, Ridzon JD, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
38
|
Théry C: Exosomes: Secreted vesicles and
intercellular communications. F100. Biol Rep. 3:152011.
|
39
|
Zhang J, Li S, Li L, Li M, Guo C, Yao J
and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and
function. Genomics Proteomics Bioinformatics. 13:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
40
|
Syn NL, Wang L, Chow EK, Lim CT and Goh
BC: Exosomes in cancer nanomedicine and immunotherapy: Prospects
and challenges. Trends Biotechnol. 35:665–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
41
|
Usman WM, Pham TC, Kwok YY, Vu LT, Ma V,
Peng B, Chan YS, Wei L, Chin SM, Azad A, et al: Efficient RNA drug
delivery using red blood cell extracellular vesicles. Nat Commun.
9:23592018. View Article : Google Scholar : PubMed/NCBI
|
42
|
Charoenviriyakul C, Takahashi Y, Morishita
M, Matsumoto A, Nishikawa M and Takakura Y: Cell type-specific and
common characteristics of exosomes derived from mouse cell lines:
Yield, physicochemical properties, and pharmacokinetics. Eur J
Pharm Sci. 96:316–322. 2017. View Article : Google Scholar
|
43
|
Smyth T, Kullberg M, Malik N, Smith-Jones
P, Graner MW and Anchordoquy TJ: Biodistribution and delivery
efficiency of unmodified tumor-derived exosomes. J Control Release.
199:145–155. 2015. View Article : Google Scholar :
|
44
|
Takahashi Y, Nishikawa M, Shinotsuka H,
Matsui Y, Ohara S, Imai T and Takakura Y: Visualization and in vivo
tracking of the exosomes of murine melanoma B16-BL6 cells in mice
after intravenous injection. J Biotechnol. 165:77–84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
45
|
Kim H, Yun N, Mun D, Kang JY, Lee SH, Park
H, Park H and Joung B: Cardiac-specific delivery by cardiac
tissue-targeting peptide-expressing exosomes. Biochem Biophys Res
Commun. 499:803–808. 2018. View Article : Google Scholar : PubMed/NCBI
|